Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Metastasis | Research article

A nomogram prediction model for lymph node metastasis in endometrial cancer patients

Authors: Zhiling Wang, Shuo Zhang, Yifei Ma, Wenhui Li, Jiguang Tian, Ting Liu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

This study aimed to explore the risk factors for lymph node metastasis (LNM) in patients with endometrial cancer (EC) and develop a clinically useful nomogram based on clinicopathological parameters to predict it.

Methods

Clinical information of patients who underwent staging surgery for EC was abstracted from Qilu Hospital of Shandong University from January 1st, 2005 to June 31st, 2019. Parameters including patient-related, tumor-related, and preoperative hematologic examination-related were analyzed by univariate and multivariate logistic regression to determine the correlation with LNM. A nomogram based on the multivariate results was constructed and underwent internal and external validation to predict the probability of LNM.

Results

The overall data from the 1517 patients who met the inclusion criteria were analyzed. 105(6.29%) patients had LNM. According the univariate analysis and multivariate logistic regression analysis, LVSI is the most predictive factor for LNM, patients with positive LVSI had 13.156-fold increased risk for LNM (95%CI:6.834–25.324; P < 0.001). The nomogram was constructed and incorporated valuable parameters including histological type, histological grade, depth of myometrial invasion, LVSI, cervical involvement, parametrial involvement, and HGB levels from training set. The nomogram was cross-validated internally by the 1000 bootstrap sample and showed good discrimination accuracy. The c-index for internal and external validation of the nomogram are 0.916(95%CI:0.849–0.982) and 0.873(95%CI:0.776–0.970), respectively.

Conclusions

We developed and validated a 7-variable nomogram with a high concordance probability to predict the risk of LNM in patients with EC.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. https://doi.org/10.3322/caac.20107.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. https://doi.org/10.3322/caac.21166.CrossRefPubMed

Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105–43.CrossRef

Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstetrics. 2009;105(2):103–4. https://doi.org/10.1016/j.ijgo.2009.02.012.CrossRef

group As, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.CrossRef

Uccella S, Podratz KC, Aletti GD, Mariani A. Re: systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2009;101(12):897–8; author reply 898-899. https://doi.org/10.1093/jnci/djp124.CrossRefPubMed

Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–16. https://doi.org/10.1093/jnci/djn397.CrossRefPubMed

Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(2):170–99. https://doi.org/10.6004/jnccn.2018.0006.CrossRef

Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506–19. https://doi.org/10.1067/mob.2000.107335.CrossRefPubMed

10.

Yang XG, Feng JT, Wang F, He X, Zhang H, Yang L, et al. Development and validation of a prognostic nomogram for the overall survival of patients living with spinal metastases. J Neuro-Oncol. 2019;145(1):167–76. https://doi.org/10.1007/s11060-019-03284-y.CrossRef

11.

Jeong SH, Kim RB, Park SY, Park J, Jung EJ, Ju YT, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. Eur J Surg Oncol. 2020;46(1):195–201. https://doi.org/10.1016/j.ejso.2019.09.143.CrossRefPubMed

12.

Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.CrossRef

13.

Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–54. https://doi.org/10.1200/JCO.2016.67.9647.CrossRefPubMed

14.

Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19(9):1141–64. https://doi.org/10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F.CrossRefPubMed

15.

Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008;109(1):11–8. https://doi.org/10.1016/j.ygyno.2008.01.023.CrossRefPubMedPubMedCentral

16.

Turan T, Hizli D, Sarici S, Boran N, Gundogdu B, Karadag B, et al. Is it possible to predict Para-aortic lymph node metastasis in endometrial cancer? Eur J Obstet Gynecol Reprod Biol. 2011;158(2):274–9. https://doi.org/10.1016/j.ejogrb.2011.04.031.CrossRefPubMed

17.

Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of Para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375(9721):1165–72. https://doi.org/10.1016/S0140-6736(09)62002-X.CrossRefPubMed

18.

Katz LA, Andrews SJ, Fanning J. Survival after multimodality treatment for stage IIIC endometrial cancer. Am J Obstet Gynecol. 2001;184(6):1071–3. https://doi.org/10.1067/mob.2001.115225.CrossRefPubMed

19.

Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 2003;13(5):664–72. https://doi.org/10.1136/ijgc-00009577-200309000-00015.CrossRefPubMed

20.

Li Y, Cong P, Wang P, Peng C, Liu M, Sun G. Risk factors for pelvic lymph node metastasis in endometrial cancer. Arch Gynecol Obstet. 2019;300(4):1007–13. https://doi.org/10.1007/s00404-019-05276-9.CrossRefPubMed

21.

Paik ES, Kim TJ, Choi CH, Kim BG, Bae DS, Lee JW. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018;29(2):e18. https://doi.org/10.3802/jgo.2018.29.e18.CrossRefPubMed

22.

Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17(5):1499–507. https://doi.org/10.1200/JCO.1999.17.5.1499.CrossRefPubMed

23.

Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002;84(3):437–42. https://doi.org/10.1006/gyno.2001.6550.CrossRefPubMed

24.

Pollom EL, Conklin CM, von Eyben R, Folkins AK, Kidd EA. Nomogram to predict risk of lymph node metastases in patients with Endometrioid endometrial Cancer. Int J Gynecol Pathol. 2016;35(5):395–401. https://doi.org/10.1097/PGP.0000000000000246.CrossRefPubMed

25.

Bendifallah S, Genin AS, Naoura I, Chabbert Buffet N, Clavel Chapelon F, Haddad B, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol. 2012;207(3):197 e191–198.CrossRef

26.

Alexander-Sefre F, Singh N, Ayhan A, Salveson HB, Wilbanks G, Jacobs IJ. Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry. J Clin Pathol. 2003;56(10):786–8. https://doi.org/10.1136/jcp.56.10.786.CrossRefPubMedPubMedCentral

27.

Karabagli P, Ugras S, Yilmaz BS, Celik C. The evaluation of reliability and contribution of frozen section pathology to staging endometrioid adenocarcinomas. Arch Gynecol Obstet. 2015;292(2):391–7. https://doi.org/10.1007/s00404-015-3621-5.CrossRefPubMed

28.

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial Cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2–30. https://doi.org/10.1097/IGC.0000000000000609.CrossRefPubMed

29.

Cox Bauer CM, Greer DM, Kram JJF, Kamelle SA. Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer. Gynecol Oncol. 2016;141(2):199–205. https://doi.org/10.1016/j.ygyno.2016.02.017.CrossRefPubMed

30.

Stalberg K, Kjolhede P, Bjurberg M, Borgfeldt C, Dahm-Kahler P, Falconer H, et al. Risk factors for lymph node metastases in women with endometrial cancer: a population-based, nation-wide register study-on behalf of the Swedish gynecological Cancer group. Int J Cancer. 2017;140(12):2693–700. https://doi.org/10.1002/ijc.30707.CrossRefPubMed

31.

Takahashi R, Mabuchi S, Kuroda H, Kozasa K, Yokoi E, Matsumoto Y, et al. The significance of pretreatment thrombocytosis and its association with neutrophilia in patients with surgically treated endometrial Cancer. Int J Gynecol Cancer. 2017;27(7):1399–407. https://doi.org/10.1097/IGC.0000000000001019.CrossRefPubMed

32.

Luo YZ, Yang Z, Qiu YL, Li XH, Qin LQ, Su QS, et al. Pretreatment triglycerides-to-high density lipoprotein cholesterol ratio in postmenopausal women with endometrial cancer. Kaohsiung J Med Sci. 2019;35(5):303–9. https://doi.org/10.1002/kjm2.12033.CrossRefPubMed

33.

Cao WM, Zheng YB, Gao Y, Ding XW, Sun Y, Huang Y, et al. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women. BMC Cancer. 2019;19(1):551. https://doi.org/10.1186/s12885-019-5765-3.CrossRefPubMedPubMedCentral

34.

Njolstad TS, Engerud H, Werner HM, Salvesen HB, Trovik J. Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. Gynecol Oncol. 2013;131(2):410–5. https://doi.org/10.1016/j.ygyno.2013.08.032.CrossRefPubMed

35.

Chen Y, Zhang L, Liu WX, Liu XY. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev. 2015;16(3):933–9. https://doi.org/10.7314/APJCP.2015.16.3.933.CrossRefPubMed

Title: A nomogram prediction model for lymph node metastasis in endometrial cancer patients
Authors: Zhiling Wang
Shuo Zhang
Yifei Ma
Wenhui Li
Jiguang Tian
Ting Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Lymphadenectomy
Endometrial Cancer
Endometrial Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08466-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer

Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model

Co-expression of low-risk HPV E6/E7 and EBV LMP-1 leads to precancerous lesions by DNA damage

Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer